Reference number : 172-2018-2019-Q1-904717, amendment number : 1, agreement type : C, recipient legal name : Phoenix Molecular Designs Ltd., recipient country : CA, recipient province : BC, recipient city : Vancouver|Vancouver, recipient postal code : V6R 1E5, program name english : Industrial Research Assistance Program – Contributions to Firms, program name french : Programme d’aide à la recherche industrielle – Contributions aux entreprises, program purpose english : The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization, program purpose french : Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation, agreement title english : Preclinical Development of the Orally Bioavailable Small Molecule RSK inhibitor PMD-026 for the Treatment of Cancer, agreement title french : Développement préclinique de l'inhibiteur PMD-026 biodisponible oralement à petite molécule RSK pour le traitement du cancer, agreement number : 904717, agreement value : 350000.0, agreement start date : 2018-04-01, agreement end date : 2019-07-31, description english : Triple-negative breast cancers (TNBC) are one of the most difficult cancers to treat, as they lack the common receptor targets for current breast cancer chemotherapies. TNBC represents 15-25% of all breast cancers, and RSK represents a novel target for TNBC. PMD-026 is a first-in-class RSK inhibitor, and the proposed Project will assess pre-clinical safety of this lead compound in relevant animal models and investigate potential drug-drug interactions, in anticipation of IND submission and human trials., description french : Développement préclinique de l'inhibiteur PMD-026 biodisponible oralement à petite molécule RSK pour le traitement du cancer, expected results english : The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization, expected results french : Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation, additional information english : This agreement has been amended 1 time(s). The total amended value is 125,000 dollars., additional information french : Cet accord a été modifié 1 fois La valeur totale des modifications est de   125 000 dollars., owner organization : nrc-cnrc, owner organization title : National Research Council Canada | Conseil national de recherches Canada